Supprelin LA

Supprelin LA is a brand name of histrelin, approved by the FDA in the following formulation(s):

SUPPRELIN LA (histrelin acetate - implant; subcutaneous)

• 
  Manufacturer: ENDO PHARM
  
  Approval date: May 3, 2007
  
  Strength(s): 50MG ^[RLD]

Has a generic version of Supprelin LA been approved?

No. There is currently no therapeutically equivalent version of Supprelin LA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Supprelin LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions and methods for treating precocious puberty
  Patent 8,062,652
  Issued: November 22, 2011
  Inventor(s): Kuzma; Petr
  Assignee(s): Endo Pharmaceuticals Solutions Inc.
  The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
  
  Patent expiration dates:
  
  
  • June 16, 2026
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 3, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Supprelin LA Implant Consumer Information (Wolters Kluwer)
• Supprelin LA implant Consumer Information (Cerner Multum)
• Supprelin LA Advanced Consumer Information (Micromedex)
• Supprelin-LA Consumer Information (Drugs.com)
• Histrelin Implant Consumer Information (Wolters Kluwer)
• Histrelin implant Consumer Information (Cerner Multum)
• Histrelin Subcutaneous Advanced Consumer Information (Micromedex)
• Histrelin acetate Subcutaneous Advanced Consumer Information (Micromedex)
• Histrelin AHFS DI Monographs (ASHP)